3 results
Approved WMORecruiting
Primary objective· • To investigate the safety and tolerability and establish either the dose of KU-0059436 which causes inhibition of PARP in combination with an active dose of carboplatin or the maximum tolerated dose (MTD) of KU-0059436 in…
Approved WMORecruiting
To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI.
Approved WMORecruiting
Primary Objective: To investigate the effects of LT4/LT3 combination therapy compared to LT4 monotherapy on tiredness in those patients with autoimmune hypothyroidism and persisting tiredness on LT4 monotherapy, after 1 year of treatment.In case it…